An innovative experimental treatment for boosting the effectiveness of blood stem-cell transplants with umbilical cord blood has a favorable safety profile in long-term animal studies, according to Harvard Stem Cell Institute (HSCI) scientists at Dana-Farber Cancer Institute (DFCI), Beth Israel Deaconess Medical Center (BIDMC), and Children’s Hospital Boston (CHB).
Analysis of long-term safety testing in nonhuman primates, published online by the journal Cell Stem Cell in a new section called “Clinical Progress,” revealed that a year following transplant umbilical cord blood units treated with a signaling molecule called 16,16-dimethyl PGE2 reconstituted all the normal types of blood cells, and none of the animals receiving treated cord blood units developed cancer. Wolfram Goessling is the first author of the paper; his HSCI colleague Trista North is the senior author.
The results of long-term safety studies in mice were previously submitted to the Food and Drug Administration to gain permission for a Phase I clinical trial under an investigational new drug (IND) application. Principal investigator Corey Cutler, a Dana-Farber transplant specialist, initiated the trial in 2009 at Dana-Farber and Massachusetts General Hospital. The IND is sponsored by Fate Therapeutics Inc. of San Diego.
Goessling and North were postdoctoral fellows in the laboratory of co-author Leonard Zon, a stem cell researcher at CHB and a scientific founder of Fate Therapeutics, when they hit upon 16,16-dimethyl PGE2 while looking for compounds that could regulate the production of hematopoietic stem cells (blood stem cells). The initial testing made use of zebrafish models.
“This is the first time a compound discovered in zebrafish has received a nod from the FDA for a clinical trial,” said Goessling.
One of the limitations of cord blood as a transplant source is that the cells engraft, or “take,” in the recipient’s bone marrow more slowly than matched donor cells form bone marrow. In addition, there is a higher failure rate for cord blood transplants. Thus there is a need for ways to improve the speed and quality of cord blood transplantation.
The research was supported by funding from the Harvard Stem Cell Institute, the National Institutes of Health, and the Howard Hughes Medical Institute.
An innovative experimental treatment for boosting the effectiveness of blood stem-cell transplants with umbilical cord blood has a favorable safety profile in long-term animal studies, according to Harvard Stem Cell Institute (HSCI) scientists at Dana-Farber Cancer Institute (DFCI), Beth Israel Deaconess Medical Center (BIDMC), and Children’s Hospital Boston (CHB).
Analysis of long-term safety testing in nonhuman primates, published online by the journal Cell Stem Cell in a new section called “Clinical Progress,” revealed that a year following transplant umbilical cord blood units treated with a signaling molecule called 16,16-dimethyl PGE2 reconstituted all the normal types of blood cells, and none of the animals receiving treated cord blood units developed cancer. Wolfram Goessling is the first author of the paper; his HSCI colleague Trista North is the senior author.
The results of long-term safety studies in mice were previously submitted to the Food and Drug Administration to gain permission for a Phase I clinical trial under an investigational new drug (IND) application. Principal investigator Corey Cutler, a Dana-Farber transplant specialist, initiated the trial in 2009 at Dana-Farber and Massachusetts General Hospital. The IND is sponsored by Fate Therapeutics Inc. of San Diego.
Goessling and North were postdoctoral fellows in the laboratory of co-author Leonard Zon, a stem cell researcher at CHB and a scientific founder of Fate Therapeutics, when they hit upon 16,16-dimethyl PGE2 while looking for compounds that could regulate the production of hematopoietic stem cells (blood stem cells). The initial testing made use of zebrafish models.
“This is the first time a compound discovered in zebrafish has received a nod from the FDA for a clinical trial,” said Goessling.
One of the limitations of cord blood as a transplant source is that the cells engraft, or “take,” in the recipient’s bone marrow more slowly than matched donor cells form bone marrow. In addition, there is a higher failure rate for cord blood transplants. Thus there is a need for ways to improve the speed and quality of cord blood transplantation.
The research was supported by funding from the Harvard Stem Cell Institute, the National Institutes of Health, and the Howard Hughes Medical Institute.
from http://news.harvard.edu/gazette/story/2011/04/better-blood/
Maybe you can find something interesting in the following sponsored links:
0 Responses to “Treatment for stem-cell transplants shows promise”
Leave a Reply